BUZZ-Humacyte rises over 40% on FDA approval for blood vessel implant** Biotech company Humacyte's HUMA.O shares rise ~44.2% to $4.99 premarket
** HUMA, late on Thursday, said the U.S. FDA approved its implant Symvess for patients with extreme blood vessel injury
** The approval was based on clinical tests where Symvess showed high rates of blood flow and low rates of infection
** HUMA says the implant can be used as a channel in patients who need to have their blood flow restored to avoid imminent limb loss
** Up to last close, stock up 21.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments